Neurogene (NASDAQ:NGNE) Reaches New 1-Year High – Here’s What Happened

Posted by Francis Steltz on Jul 10th, 2026

Neurogene Inc. (NASDAQ:NGNE – Get Free Report) shares hit a new 52-week high on Wednesday . The stock traded as high as $37.69 and last traded at $38.57, with a volume of 20899 shares changing hands. The stock had previously closed at $36.80.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Canaccord Genuity Group lowered their price objective on Neurogene to $180.00 and set a “buy” rating on the stock in a research report on Monday, April 6th. Guggenheim began coverage on Neurogene in a report on Tuesday, April 28th. They issued a “buy” rating and a $69.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of Neurogene in a research note on Tuesday, June 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a report on Tuesday, April 21st. Finally, UBS Group set a $70.00 price objective on Neurogene in a research report on Wednesday, June 3rd. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Neurogene presently has an average rating of “Buy” and a consensus target price of $84.83.

View Our Latest Stock Analysis on NGNE

Neurogene Stock Performance

The stock has a market cap of $676.96 million, a P/E ratio of -9.42 and a beta of 1.68. The business’s 50-day moving average price is $30.23 and its 200-day moving average price is $23.86.

Neurogene (NASDAQ:NGNE – Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.09). As a group, equities research analysts expect that Neurogene Inc. will post -5.63 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Christine Mikail Cvijic sold 4,200 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $36.13, for a total value of $151,746.00. Following the transaction, the chief financial officer owned 84,040 shares of the company’s stock, valued at $3,036,365.20. This trade represents a 4.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 19,200 shares of company stock valued at $639,932 in the last three months. Corporate insiders own 11.68% of the company’s stock.

Institutional Investors Weigh In On Neurogene

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its stake in Neurogene by 89.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock worth $36,000 after acquiring an additional 978 shares during the period. ADAR1 Capital Management LLC boosted its position in shares of Neurogene by 3.4% in the third quarter. ADAR1 Capital Management LLC now owns 30,633 shares of the company’s stock worth $531,000 after purchasing an additional 1,008 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Neurogene by 17.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after purchasing an additional 1,059 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Neurogene by 12.8% in the first quarter. Bank of New York Mellon Corp now owns 26,043 shares of the company’s stock worth $525,000 after purchasing an additional 2,950 shares in the last quarter. Finally, Daiwa Securities Group Inc. bought a new stake in shares of Neurogene during the 4th quarter valued at $66,000. 52.37% of the stock is owned by hedge funds and other institutional investors.

Neurogene Company Profile

(Get Free Report)

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.